Superworth

Arrowhead Pharmaceuticals PE ratio ARWR

Share price divided by earnings per share over the last twelve months, since 2019.

Today, Oct 23, 2026
n/m
losses over the last year
Last meaningful
48.6×
May 2026
7-year median
79.4×
7-year range
35.7× to 490×
Peer median
60.3×

Arrowhead Pharmaceuticals has no meaningful PE ratio today: it lost $2.24 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in May 2026, at 48.6×.

On the days it had one over the last 7 years, its median was 79.4×, from 35.7× in Mar 2026 to 490× in Jul 2020.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far48.6×35.7×48.6×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020431×48.4×490×
201992.8×58.6×422×

Against its peers

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

CompanyPE ratio
ARWRArrowhead Pharmaceuticalsn/m
TGTXTG Therapeutics19.8×
PTGXProtagonist Therapeutics134×
ALKSAlkermes plc.115×
CORTCorcept Therapeutics204×
AMRXAmneal Pharmaceuticals41.6×
BMRNBiomarin Pharmaceutical151×
LGNDLigand Pharmaceuticals32.3×
KNSAKiniksa Pharmaceuticals International79.1×
JAZZJazz Pharmaceuticals14.6×
INDVIndivior Pharmaceuticals12.4×
Peer median60.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Arrowhead Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.